| Description | LY2886721, a BACE inhibitor, is used for the therapy of Alzheimer's Disease. |
| In vitro | LY2886721 is an oral, small molecule of β-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the Clinicalal progression of AD. [1] LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid. [2] |
| Target activity | BACE1:20.3 nM, BACE2:10.2 nM |
| molecular weight | 390.41 |
| Molecular formula | C18H16F2N4O2S |
| CAS | 1262036-50-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 1 mg/ml, Sonication is recommended. |
| References | 2. Townsend M, et al. J Alzheimers Dis, 2011, 24 Suppl 2, 43-52. |